VB

Vilin Bio Med Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Vilin Bio Med Q2 Results 2026 (FY27) statement: Revenue & Margins

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Vilin Bio Med Ltd Q2 FY27 key numbers

Revenue
Revenue from Operations for the quarter ended September 30, 2026: Rs. 3,260.00 lakhs (Standalone and Consolidated).

As stated in Vilin Bio Med Ltd's Q2 FY27 results statement · published 15 Nov 2026. Reported figures, not investment advice.

Based on Vilin Bio Med Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

Price₹53
Market cap₹81 Cr
P/E41.8

The short version

Revenue from Operations for the quarter ended September 30, 2026: Rs. 3,260.00 lakhs (Standalone and Consolidated). EBITDA for the quarter ended September 30, 2026: Rs. 179.77 lakhs, up 147% YoY (from Rs. 72.82 lakhs).

From Vilin Bio Med Ltd's Q2 FY27 earnings-call transcript · updated 15 Nov 2026.

How did Vilin Bio Med's revenue grow in the September 2026 quarter?

  • Revenue from Operations for the quarter ended September 30, 2026: Rs. 3,260.00 lakhs (Standalone and Consolidated)
  • Revenue for the same quarter in the previous year (September 30, 2025): Rs. 966.40 lakhs
  • Year-on-Year Increase in Revenue: Rs. 2,293.60 lakhs (approximately 238% increase)

What happened to Vilin Bio Med's margins in Q2 FY27?

See what Vilin Bio Med Ltd said on profitability & margins — free account, 30 seconds.

What capex is Vilin Bio Med planning?

See what Vilin Bio Med Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Vilin Bio Med raising money or cutting debt?

See what Vilin Bio Med Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Vilin Bio Med's order book?

Specifically: - It includes statements on revenue, expenses, profit, assets, liabilities, and cash flow but lacks details on operational order status.

More Q2 FY27 results in Pharmaceuticals & Biotechnology

All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Vilin Bio Med Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Vilin Bio Med Ltd Q2 FY27 results?

Revenue from Operations for the quarter ended September 30, 2026: Rs. 3,260.00 lakhs (Standalone and Consolidated). EBITDA for the quarter ended September 30, 2026: Rs. 179.77 lakhs, up 147% YoY (from Rs. 72.82 lakhs).

What is Vilin Bio Med Ltd share price analysis?

Vilin Bio Med Ltd currently shows a neutral. The stock trades at a P/E of 41.8 with a market cap of ₹81 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Vilin Bio Med Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.